Neoantigen targeted therapies market projected to reach USD 3 Billion by 2030(Roots)

Roots Analysis has announced the addition of “Neoantigen Targeted Therapies, 2019-2030” report to its list of offerings.

The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response. Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 320+ page report, which features 110+ figures and 140+ tables, please visit this –

Key Market Insights

Over 150+ candidate therapies in the development pipeline
Nearly 13% of the pipeline therapies are being developed for the treatment of GI cancers, followed by lung cancer (11%). Examples of molecules being developed for the aforementioned indications include (in alphabetical order, no specific selection criteria) MicOryx, NCI-4650, and Tedopi®.

1,100+ patents filed / granted in 2018
In fact, more than 6,000 patents were filed / granted related to neoantigen targeted therapies, since 1978. Based on existing intellectual property, the R&D activity was observed to be concentrated in the US. Other key regions with significant intellectual capital include (in decreasing order of number of patents filed / granted) Australia, Europe, China, and Canada.

Close to USD 7.5 billion invested by both private and public investors, since 2014


Gaurav Chaudhary

+1 (415) 800 3415

Leave a Reply

Your email address will not be published. Required fields are marked *